Co-hosts Charu Aggarwal and Jack West are joined by guest expert Sanjay Popat to discuss how practice should change and open questions on molecular testing and adjuvant EGFR inhibitor osimertinib for resected early stage EGFR mutation-positive NSCLC.
Dr. Sanjay Popat, Debating With Us Where the Dust Has Settled with Adjuvant Osimertinib After the ADAURA Trial | BTJ-003
